

From: Harris, Paul
Sent: Thursday, July 31, 2014 3:12 PM
To: 'Bonthron, David'
Subject: A Fumble Occurred : Blind Sample Question

David,

I have no record of myself responding to you about this question of yours. I am sorry that I dropped the ball.

As stated in the Statement of Considerations (73 FR 17105, dated March 31, 2008) for the 2008 Rule, "The NRC has made these changes in § 26.168(b)-(g) to increase the ability of licensees and other entities to independently monitor the ability of their HHS-certified laboratories to consistently identify positive, adulterated, dilute, and substituted specimens and hold false negatives to a minimum." We get many 30-days reports on blinds that occur without resolution because the blind supplier says one thing and the lab says another and the a second lab says something different.

R,
Paul

Paul Harris

**U.S. Nuclear Regulatory Commission / Office of Nuclear Security and Incident Response
Division of Security Policy / Security Programs Support Branch
Senior Program Manager, Fitness for Duty Programs**

|  E-mail: Paul.Harris@NRC.gov |  Office: (301) 287-9294 |  Fax: (301) 287-9347 |  Cell: (240) 498-9691

The information in this response is provided as a public service and solely for informational purposes and is not, nor should be deemed as, an official NRC position, opinion or guidance, or "a written interpretation by the General Counsel" under 10 CFR 26.7, on any matter to which the information may relate. The opinions, representations, positions, interpretations, guidance or recommendations which may be expressed by the NRC technical staff responding to an inquiry are solely the NRC technical staff's and do not necessarily represent the same for the NRC. Accordingly, the fact that the information was obtained through the NRC technical staff will not have a precedential effect in any legal or regulatory proceeding.

From: Bonthron, David [<mailto:David.Bonthron@fpl.com>]
Sent: Wednesday, May 21, 2014 4:10 PM
To: Harris, Paul
Subject: Blind Sample Question

Paul,

I hope all is well with you and that you will be able to join us in Columbus.

I have no current or past issues with the below but more of a question at the moment on blind specimens and in particular, "negatives" believe it or not. Since I am not a scientist or involved in the day to day activity of supplying blinds, what is the reason for conducting "confirmatory testing" as it states in 26.168(g)(1) as seen below on a [negative](#)? Just curious ...

26.168

(g) Licensees and other entities shall use only blind performance test samples that have been certified by the supplier to be—

(1) Negative. A negative blind performance test sample may not contain a measurable amount of a target drug analyte and must be certified by immunoassay and **confirmatory testing**

Thank you,

David

David J. Bonthron
Manager
FPL/NextEra
Fleet AA/FFD Programs
(561) 694-3355 - Office
(772) 201-0305 - Cell

The transmission is intended to be delivered only to the named addressee(s) and may contain information that is confidential. If this information is received by anyone other than the named addressee(s), the recipient should immediately notify the sender by E-MAIL and by telephone (561) 694-3355 and permanently delete the original and any copy, including printout of the information. In no event shall this material be read, used, copied, reproduced, stored or retained by anyone other than the named addressee(s), except with the express consent of the sender or the named addressee(s).